Melissa Fleury

This inventor holds 92 USPTO granted patents and 7 published patent applications, plus 9 CIPO patents and 24 EPO patents, primarily in JAK Kinase Inhibitors (CPC class A61K45-06). Top assignees: Theravance Biopharma R&d IP, LLC, Theravance, Inc., Theravance Respiratory Company, LLC. Active years: 2011-2025.

USPTO Granted Patents = 92 (Patent Applications = 7)

% Patents Active = 63.0

CIPO Patents = 9 (Patent Applications = 12)

EPO Patents = 24 (Patent Applications = 25)

Average Co-Inventor Count = 3.8

ph-index = 16

Forward Citations = 869(Granted Patents)

Forward Citations (Not Self Cited) = 173(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Mateo, CA (US) (2012)
San Francisco, CA (US) (2011 - 2017)
Brisbane, CA (US) (2015 - 2024)

Company Filing History:

74 out of 262

Theravance Biopharma R&d IP, LLC

Theravance Respiratory Company, LLC

patents

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

JAK Kinase

Neprilysin Inhibitors

Diamide Compounds

Muscarinic Receptor Antagonist

Beta2 Adrenergic Agonist

Pyrimidine Compounds

Respiratory Disease

Crystalline Compounds

92 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor (2025-07-15),

2. 12351561 - Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2025-07-08),

3. 12016835 - Neprilysin inhibitors (2024-06-25),

4. 11919888 - Neprilysin inhibitors (2024-03-05),

5. 11851443 - Neprilysin inhibitors (2023-12-26),

6. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease (2023-08-08),

7. 11718591 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof (2023-08-08),

8. 11642332 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2023-05-09),

9. 11634413 - Neprilysin inhibitors (2023-04-25),

10. 11547687 - Neprilysin inhibitors (2023-01-10),

11. 11299492 - JAK kinase inhibitor compounds for treatment of respiratory disease (2022-04-12),

12. 11261197 - Neprilysin inhibitors (2022-03-01),

13. 11230536 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2022-01-25),

14. 11174219 - Neprilysin inhibitors (2021-11-16),

15. 11124502 - Neprilysin inhibitors (2021-09-21),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, and patents, I am here to assist you.

Title: Melissa Fleury: Pioneering Inventor in Neprilysin Inhibitors

Introduction:

Melissa Fleury, a brilliant inventor based in Brisbane, CA, has made significant strides in the field of pharmaceuticals. With a remarkable portfolio of 89 patents, Melissa is known for her groundbreaking work in neprilysin inhibitors.

Latest Patents:

In her latest patents, Melissa has introduced compounds with formulas aimed at neprilysin inhibition activity. These compounds, along with their pharmaceutical compositions, are paving the way for innovative treatment methods and processes in the medical industry.

Career Highlights:

Melissa's career highlights include her tenure at Theravance Biopharma R&D IP, LLC, and Theravance, Inc. Her expertise and dedication have been instrumental in the development of cutting-edge pharmaceutical solutions that have the potential to revolutionize the treatment of various medical conditions.

Collaborations:

Throughout her career, Melissa has collaborated with esteemed professionals in the field, including coworkers such as Adam D Hughes and Roland Gendron. These collaborations have led to a synergistic approach to innovation, resulting in the successful implementation of new ideas and technologies.

Conclusion:

In conclusion, Melissa Fleury stands out as a trailblazing inventor in the realm of neprilysin inhibitors. Her passion for innovation, coupled with her exceptional talent, has positioned her as a key figure in driving advancements in the pharmaceutical industry. Melissa's continued dedication to pushing boundaries and creating solutions underscores her importance in shaping the future of healthcare.